Navigation Links
Regulatory molecule for tumor formation or suppression identified by Singapore, US researchers
Date:3/17/2009

One of the small regulatory molecules, named microRNA-125b, is a novel regulator of p53, an important protein that safeguards cells against cancers, Singapore and U.S. scientists report in the March 17, 2009 issue of the journal Genes & Development.

The scientists found that during embryonic development, this microRNA keeps the level of p53 low to avoid excessive cell death.

But, if the DNA is damaged, the microRNA level is reduced to allow an increase in p53, which eliminates damaged cells and thus prevents tumor formation.

The research was conducted with zebrafish.

"Interestingly, this microRNA is elevated in many types of human cancers, suggesting that it may contribute to the formation of tumours by suppressing the p53 protein," said Bing Lim, M.D., Ph.D., lead author and senior group leader at the Genome Institute of Singapore (GIS), a research institute under the Agency for Science, Technology and Research (A*STAR).

"Hence, our findings have important implications in the diagnosis and treatment of cancers," he added. "The significance of this finding, of course, once again emphasizes the relevance and importance of research linking microRNAs to many subspecialties of human medicine, including cancer and regenerative medicine."

Harvard Medical School's Judy Lieberman, M.D., Ph.D., said, "This important study provides an elegant and beautifully worked out example of the role of microRNAs in master-minding how a cell responds to environmental cues and developmental signals.

"The implication of this study is that these small molecules might be mimicked or antagonized as drugs to treat serious diseases for which no effective treatment exists at present," added Dr. Lieberman, senior investigator at the Immune Disease Institute, and Professor of Pediatrics and Director of the Division of AIDS at Harvard. She is not a co-author of the paper.

Professor of Cell Biology at the Harvard
'/>"/>

Contact: Cathy Yarbrough
sciencematter@yahoo.com
858-243-1814
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Page: 1 2

Related biology news :

1. Type 1 diabetes triggered by lazy regulatory T-cells: McGill researchers
2. Use of nanomaterials in food packaging poses regulatory challenges
3. New regulatory mechanism discovered for cell identify and behavior in forming organs
4. Caltech researchers help unlock the secrets of gene regulatory networks
5. New data suggest jumping genes play a significant role in gene regulatory networks
6. Food counterfeiting, contamination outpace international regulatory systems
7. Memory molecule stores memories in neocortex
8. Clemson scientists shed light on molecules in living cells
9. Model for the assembly of advanced, single-molecule-based electronic components developed at Pitt
10. Botched production of insulin molecule may lead to diabetes
11. New molecules discovered that block cancer cells from modifying cell DNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... DENVER , Oct. 20, 2014  Leading identity ... years time half of the world,s population will have ... in Europe . Asia ... dominate the market accounting for more than 60% of ... Acuity,s report  -- "The Global National ...
(Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
(Date:10/17/2014)... critical and pertinent for practicing physicians and clinicians given ... The Journal, Disaster Medicine and Public Health Preparedness ... Public Health, to surround the public, medical professionals and ... , On October 17, the journal published ... was prepared by Dr. Eric Toner, internist and emergency ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Researchers find why depression and aging linked to increased disease risk 2
... Troy, N.Y. Engineering researchers at Rensselaer Polytechnic Institute ... diverse areas to help create a closed-loop artificial pancreas. ... administer insulin to patients with Type 1 diabetes, and ... living with the chronic disease. For six years, ...
... A study conducted by VTT Technical Research Centre of Finland ... grades 95E10 and 98E5 sold in Finland as regards fuel ... tests conducted by VTT using six used cars of different ... claimed in public that fuel consumption is significantly higher with ...
... a low-cost healthy lifestyle program, including self-weighing weekly or ... them from gaining too much weight during early pregnancy. ... Endocrine Society,s 93rd Annual Meeting in Boston. "Preventing ... health of all mothers and their babies and can ...
Cached Biology News:Engineering new weapons in the fight against juvenile diabetes 2Engineering new weapons in the fight against juvenile diabetes 3VTT: No significant difference in car fuel consumption between E10 and E5 petrol grades 2Pregnant women can prevent excess weight gain with simple steps, study finds 2
(Date:10/25/2014)... Investor-Edge has initiated coverage on ... ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ), ... Pharmaceuticals Inc. (NASDAQ: PPHM ), and StemCells ... can be accessed at: http://investor-edge.com/register . ... on a positive note as the Dow Jones Industrial ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... and Rhythm, a biopharmaceutical company, today announced that Actavis ... wholly owned subsidiary, Rhythm Health, Inc., which is developing ... of diabetic gastroparesis and other GI functional disorders. ... trial of relamorelin for the treatment of diabetic gastroparesis ...
(Date:10/22/2014)... NJ (PRWEB) October 22, 2014 ... and services – has been working with a team ... and New Haven Farms Community Farming Collaborative to provide ... ePRO solution. The study, which started in May, ... program that provides participants weekly exposure to and participation ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... Aug. 3, 2011 Neuralstem, Inc. (NYSE Amex: ... of Defense (DOD) contract to develop its human neural ... tumors. The research contract, entitled "Research to Treat Cancerous ... out in collaboration with Principal Investigator John Zhang, MD, ...
... 2011 Cambrex Corporation (NYSE: CBM ) reports second ... Highlights Reported sales increased by ... compared to the second quarter of 2010. EBITDA was $13.2 ... compared to $12.1 million in the second quarter of 2010. ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ... on Monday, August 8, 2011, after the U.S. financial markets ... webcast on Monday, August 8, 2011, at 5:00 p.m. Eastern ... and highlights.  A live webcast of the call will be ...
Cached Biology Technology:Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3Cambrex Reports Second Quarter of 2011 Results 2Cambrex Reports Second Quarter of 2011 Results 3Cambrex Reports Second Quarter of 2011 Results 4Cambrex Reports Second Quarter of 2011 Results 5Cambrex Reports Second Quarter of 2011 Results 6Cambrex Reports Second Quarter of 2011 Results 7Cambrex Reports Second Quarter of 2011 Results 8Anadys Pharmaceuticals to Report Second Quarter 2011 Financial Results 2
... a concentrated formulation of a rinsing buffer ... technology, as well as for manual immunostaining. ... Brigati M.D., Department of Pathology, University of ... recommended for all the rinsing steps performed ...
... MALDI O-TOF creates a new category for ... platform that has been licensed to the ... Manitoba. , As the first single MALDI-TOF ... collisional cooling, the prOTOF 2000 represents a ...
... miVac DNA is an ideal small concentrator ... concentrator capable of removing water and organic ... including tubes, microplates, vials and round bottom ... for the busy lab. ,The built-in special ...
... The H2OBIT™ is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
Biology Products: